Concomitant autoimmunity and risk of multiple sclerosis disability worsening
- PMID: 38761694
- DOI: 10.1016/j.msard.2024.105637
Concomitant autoimmunity and risk of multiple sclerosis disability worsening
Abstract
Background: Few studies have examined the effect of concomitant autoimmune diseases on multiple sclerosis (MS) disability worsening. We set out to examine whether concomitant Crohn's Disease (CD), Ulcerative Colitis (UC), or Type 1 Diabetes (T1D) affect MS disability worsening in a nationwide cohort of MS patients as defined by reaching expanded disability scale status (EDSS) scores 3.0, 4.0 and 6.0.
Methods: Patients with MS onset between January 2004 and January 2019 were identified from the Swedish MS registry and the Swedish National Patient Register. Kaplan-Meier analysis was used to estimate the median time to reach sustained disability milestones. Adjusted Cox proportional hazard regression models were used to calculate the risk of reaching disability milestones among persons with and without CD, UC, or T1D.
Results: Out of 8972 persons with MS, 88 (1.0 %) had T1D, 47 (0.8 %) had UC, and 78 (0.9 %) had CD. There was a significantly higher risk of disability progression, for persons with MS and T1D for reaching EDSS 6.0, hazard ratio (HR) = 2.21 (95 % confidence interval (CI) = 1.48 -3.31) and persons with MS and comorbid CD for reaching EDSS 3.0, HR = 2.30 (95 %CI = 1.74-3.04) and 4.0, HR = 1.59 (95 %CI = 1.09-2.32), and persons with MS and comorbid UC for reaching EDSS 3.0 HR = 1.57 (95 %CI = 1.15-2.14). As defined by Charlson's comorbidity index, the co-existence of other co-morbidities conferred a significant increase in the risk of reaching all endpoints, with HR ranging from 1.23 to 1.62.
Conclusion: Comorbidity is associated with a significantly increased risk of reaching disability end-points, and T1D, CD, and UC increase the risk further. Thus, there appears to be a need for increased vigilance of comorbidites in persons with MS in order to optimise the long-term outcome of MS.
Keywords: Comorbidities; Epidemiology; Mulitple sclerosis; Risk factors.
Copyright © 2024. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest The authors declare that there is no conflict of interest.
Similar articles
-
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.Mult Scler Relat Disord. 2020 May;40:101956. doi: 10.1016/j.msard.2020.101956. Epub 2020 Jan 17. Mult Scler Relat Disord. 2020. PMID: 32007654
-
Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.Neurology. 2019 Dec 10;93(24):e2216-e2223. doi: 10.1212/WNL.0000000000008617. Epub 2019 Nov 8. Neurology. 2019. PMID: 31704791 Free PMC article.
-
Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.JAMA Neurol. 2019 Jun 1;76(6):665-671. doi: 10.1001/jamaneurol.2019.0330. JAMA Neurol. 2019. PMID: 30882868 Free PMC article.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Incidence and prevalence of autoimmune diseases in China: A systematic review and meta-analysis of epidemiological studies.Glob Epidemiol. 2024 Aug 9;8:100158. doi: 10.1016/j.gloepi.2024.100158. eCollection 2024 Dec. Glob Epidemiol. 2024. PMID: 39286340 Free PMC article. Review.
Cited by
-
The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.J Neurol. 2025 Sep 3;272(9):607. doi: 10.1007/s00415-025-13351-2. J Neurol. 2025. PMID: 40900203 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials